Trial Profile
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution 3 mg/mL, 30 mg/mL, and 50 mg/mL in Patients With Dry Eye Disease (DED)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs AXR-159 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors AxeroVision
- 12 Jan 2021 Status changed from active, no longer recruiting to completed.
- 22 Sep 2020 Planned End Date changed from 1 Apr 2019 to 30 Oct 2021.
- 22 Sep 2020 Planned primary completion date changed from 1 Mar 2019 to 30 Oct 2021.